Answers are grounded in this paper and cite their sources.
A semi-annual surveillance scheme from age 25 to 30 years is offered to BRCA1/BRCA2 pathogenic sequence variants (PSVs) carriers for early detection of breast cancer (BC). There is a paucity of data on the yield of adhering to this scheme beyond 70 years of age.
No takes yet. Share an insight, caveat, or question.
Bufman et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: